1.
Pre- and post-surgery serum angiogenic activity measured by proliferative activity on HUVE cells (PA expressed as % of control serum PA) mean ± S.D.) and VEGF levels (pg/ml; median, interquartile range) in patients with colorectal carcinoma (CRC) compared to patients who underwent surgery for non-malignant colorectal diseases (SC) and healthy individuals
| Pre-surgery | 8 hrs post-surgery | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | n | PA | VEGF | n | PA | VEGF | |||||
| CRC | 53 | 213 ± 41† | 251(160–357)†† | 48 | 186 ± 47† | 280(176–450)†† | |||||
| Primary tumour location | |||||||||||
| Colon | 29 | 208 ± 47 | 250(156–301) | 25 | 186 ± 50 | 250(166–449) | |||||
| Rectum | 24 | 220 ± 34 | 260(161–435) | 23 | 186 ± 44 | 297(181–535) | |||||
| Surgery | |||||||||||
| Curative | 42 | 212 ± 42 | 251(158–354) | 39 | 191 ± 41 | 275(174–448) | |||||
| Palliative | 11 | 216 ± 41 | 266(167–493) | 9 | 166 ± 64 | 334(192–850) | |||||
| Lymph node metastases | |||||||||||
| Absent | 36 | 214 ± 42 | 249(113–318) | 34 | 194 ± 40 | 258(141–390) | |||||
| Present | 13 | 214 ± 40 | 266(176–479) | 13 | 159 ± 58§ | 370(204–708) | |||||
| Distant metastases | |||||||||||
| Absent | 45 | 212 ± 41 | 253(160–376) | 42 | 190 ± 41 | 280(179–455) | |||||
| Present | 8 | 218 ± 44 | 215(132–292) | 6 | 155 ± 72 | 281(153–402) | |||||
| Serum proliferative activity | |||||||||||
| High (>250) | 9 | 243(155–372) | 9 | 203(147–362) | |||||||
| Low (<250) | 44 | 252(160–352) | 39 | 310(180–470) | |||||||
| SC | 16 | 197 ± 53‡ | 183(115–467)‡‡ | 15 | 171 ± 51‡ | 190(97–550)‡‡ | |||||
| Healthy individuals | 34 | 201 ± 37 | 162(133–241) | ||||||||
†Pre-surgery versus 8 hrs post-surgery PA values in CRC (P < 0.001) and in ‡SC patients (P= 0.036) (Student's test) §absent versus present lymph node metastases PA values (P= 0.024; Student's test), †† pre-surgery versus 8 hrs post-surgery VEGF levels in CRC (P= 0.004) and in ‡‡SC patients (P= 0.001; Wilcoxon's test).